The use of bevacizumab (Avastin®, Genentech Inc., San Francisco, CA), an anti-VEGF agent, to treat neovascularization in PDR began to popularize following its reported success in treating neovascular age-related macular degeneration [10–12]. The gene discussed is VEGFA; the disease is age-related macular degeneration.